Login Register Cart 0
Research Article

丝氨酸蛋白酶27:泛癌预后生物标志物，与乳腺癌侵袭性进展相关

卷 31, 期 15, 2024

发表于: 27 October, 2023

页: [2073 - 2089] 页: 17

弟呕挨: 10.2174/0929867330666230324161329

价格: $65

摘要

背景:为了创造有效的药物，研究人员必须首先确定驱动人类癌症致癌过程的共同或独特基因。丝氨酸蛋白酶27 (PRSS27)最近被确定为食管鳞状细胞癌的可能驱动基因。然而，到目前为止，还没有进行全面的泛癌症研究，包括乳腺癌。 方法:利用TCGA (the Cancer Genome Atlas)、GEO (Gene Expression Omnibus)数据集和多种生物信息学工具，研究PRSS27在33种肿瘤中的功能。此外，我们还对PRSS27在乳腺癌中的预后进行了分析，并通过体外实验验证了其作为致癌基因的作用。我们首先探索了PRSS27在10多种肿瘤中的表达，然后我们研究了PRSS27的基因组突变。 结果:我们发现PRSS27在乳腺癌及其他癌症的生存中具有预后意义，并结合一组确定的临床因素建立了乳腺癌预后预测模型。此外，我们通过一些体外实验证实了PRSS27是乳腺癌的致癌基因。 结论:我们的泛癌症调查全面回顾了PRSS27在各种人类恶性肿瘤中的致癌功能，提示它可能是一种有前景的乳腺癌预后生物标志物和肿瘤治疗靶点。

关键词: PRSS27，泛癌，乳腺癌，预后，IL-17信号通路，致癌过程。

« Previous Next »
[1]
Bhagwandin, V.J.; Hau, L.W.; Mallen-St, C.J.; Wolters, P.J.; Caughey, G.H. Structure and activity of human pancreasin, a novel tryptic serine peptidase expressed primarily by the pancreas. J. Biol. Chem., 2003, 278(5), 3363-3371.
[http://dx.doi.org/10.1074/jbc.M209353200] [PMID: 12441343]
[2]
Kataoka, A.; Yamada, K.; Hagiwara, T.; Terayama, M.; Sugimoto, T.; Nohara, K.; Igari, T.; Yokoi, C.; Kawamura, Y.I. Expression status of serine protease 27: A prognostic marker for esophageal squamous cell carcinoma treated with preoperative chemotherapy/chemoradiotherapy. Ann. Surg. Oncol., 2021, 28(9), 5373-5381.
[http://dx.doi.org/10.1245/s10434-020-09550-y] [PMID: 33452606]
[3]
Raman, K.; Trivedi, N.N.; Raymond, W.W.; Ganesan, R.; Kirchhofer, D.; Verghese, G.M.; Craik, C.S.; Schneider, E.L.; Nimishakavi, S.; Caughey, G.H. Mutational tail loss is an evolutionary mechanism for liberating marapsins and other type I serine proteases from transmembrane anchors. J. Biol. Chem., 2013, 288(15), 10588-10598.
[http://dx.doi.org/10.1074/jbc.M112.449033] [PMID: 23447538]
[4]
Britt, K.L.; Cuzick, J.; Phillips, K.A. Key steps for effective breast cancer prevention. Nat. Rev. Cancer, 2020, 20(8), 417-436.
[http://dx.doi.org/10.1038/s41568-020-0266-x] [PMID: 32528185]
[5]
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[6]
Loibl, S.; Poortmans, P.; Morrow, M.; Denkert, C.; Curigliano, G. Breast cancer. Lancet, 2021, 397(10286), 1750-1769.
[http://dx.doi.org/10.1016/S0140-6736(20)32381-3] [PMID: 33812473]
[7]
Borri, F.; Granaglia, A. Pathology of triple negative breast cancer. Semin. Cancer Biol., 2021, 72, 136-145.
[http://dx.doi.org/10.1016/j.semcancer.2020.06.005] [PMID: 32544511]
[8]
Atakpa, E.C.; Thorat, M.A.; Cuzick, J.; Brentnall, A.R. Mammographic density, endocrine therapy and breast cancer risk: A prognostic and predictive biomarker review. Cochrane Database Syst. Rev., 2021, 10(10), CD013091.
[PMID: 34697802]
[9]
Zhao, J.; Chen, X.; Herjan, T.; Li, X. The role of interleukin-17 in tumor development and progression. J. Exp. Med., 2020, 217(1), e20190297.
[http://dx.doi.org/10.1084/jem.20190297] [PMID: 31727782]
[10]
Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin., 2022, 72(1), 7-33.
[http://dx.doi.org/10.3322/caac.21708] [PMID: 35020204]
[11]
Yin, L.; Duan, J.J.; Bian, X.W.; Yu, S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res., 2020, 22(1), 61.
[http://dx.doi.org/10.1186/s13058-020-01296-5] [PMID: 32517735]
[12]
Lyons, T.G. Targeted therapies for triple-negative breast cancer. Curr. Treat. Options Oncol., 2019, 20(11), 82.
[http://dx.doi.org/10.1007/s11864-019-0682-x] [PMID: 31754897]
[13]
Tutt, A.; Tovey, H.; Cheang, M.C.U.; Kernaghan, S.; Kilburn, L.; Gazinska, P.; Owen, J.; Abraham, J.; Barrett, S.; Barrett-Lee, P.; Brown, R.; Chan, S.; Dowsett, M.; Flanagan, J.M.; Fox, L.; Grigoriadis, A.; Gutin, A.; Harper-Wynne, C.; Hatton, M.Q.; Hoadley, K.A.; Parikh, J.; Parker, P.; Perou, C.M.; Roylance, R.; Shah, V.; Shaw, A.; Smith, I.E.; Timms, K.M.; Wardley, A.M.; Wilson, G.; Gillett, C.; Lanchbury, J.S.; Ashworth, A.; Rahman, N.; Harries, M.; Ellis, P.; Pinder, S.E.; Bliss, J.M. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial. Nat. Med., 2018, 24(5), 628-637.
[http://dx.doi.org/10.1038/s41591-018-0009-7] [PMID: 29713086]
[14]
Gerratana, L.; Basile, D.; Buono, G.; De Placido, S.; Giuliano, M.; Minichillo, S.; Coinu, A.; Martorana, F.; De Santo, I.; Del Mastro, L.; De Laurentiis, M.; Puglisi, F.; Arpino, G. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treat. Rev., 2018, 68, 102-110.
[http://dx.doi.org/10.1016/j.ctrv.2018.06.005] [PMID: 29940524]
[15]
Costa, R.L.B.; Han, H.S.; Gradishar, W.J. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: A review. Breast Cancer Res. Treat., 2018, 169(3), 397-406.
[http://dx.doi.org/10.1007/s10549-018-4697-y] [PMID: 29417298]
[16]
Bardia, A.; Hurvitz, S.A.; Tolaney, S.M.; Loirat, D.; Punie, K.; Oliveira, M.; Brufsky, A.; Sardesai, S.D.; Kalinsky, K.; Zelnak, A.B.; Weaver, R.; Traina, T.; Dalenc, F.; Aftimos, P.; Lynce, F.; Diab, S.; Cortés, J.; O’Shaughnessy, J.; Diéras, V.; Ferrario, C.; Schmid, P.; Carey, L.A.; Gianni, L.; Piccart, M.J.; Loibl, S.; Goldenberg, D.M.; Hong, Q.; Olivo, M.S.; Itri, L.M.; Rugo, H.S. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med., 2021, 384(16), 1529-1541.
[http://dx.doi.org/10.1056/NEJMoa2028485] [PMID: 33882206]
[17]
Voorwerk, L.; Slagter, M.; Horlings, H.M.; Sikorska, K.; van de Vijver, K.K.; de Maaker, M.; Nederlof, I.; Kluin, R.J.C.; Warren, S.; Ong, S.; Wiersma, T.G.; Russell, N.S.; Lalezari, F.; Schouten, P.C.; Bakker, N.A.M.; Ketelaars, S.L.C.; Peters, D.; Lange, C.A.H.; van Werkhoven, E.; van Tinteren, H.; Mandjes, I.A.M.; Kemper, I.; Onderwater, S.; Chalabi, M.; Wilgenhof, S.; Haanen, J.B.A.G.; Salgado, R.; de Visser, K.E.; Sonke, G.S.; Wessels, L.F.A.; Linn, S.C.; Schumacher, T.N.; Blank, C.U.; Kok, M. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: The TONIC trial. Nat. Med., 2019, 25(6), 920-928.
[http://dx.doi.org/10.1038/s41591-019-0432-4] [PMID: 31086347]
[18]
Li, W.; Danilenko, D.M.; Bunting, S.; Ganesan, R.; Sa, S.; Ferrando, R.; Wu, T.D.; Kolumam, G.A.; Ouyang, W.; Kirchhofer, D. The serine protease marapsin is expressed in stratified squamous epithelia and is up-regulated in the hyperproliferative epidermis of psoriasis and regenerating wounds. J. Biol. Chem., 2009, 284(1), 218-228.
[http://dx.doi.org/10.1074/jbc.M806267200] [PMID: 18948266]
[19]
Adachi, W.; Ulanovsky, H.; Li, Y.; Norman, B.; Davis, J.; Piatigorsky, J. Serial analysis of gene expression (SAGE) in the rat limbal and central corneal epithelium. Invest. Ophthalmol. Vis. Sci., 2006, 47(9), 3801-3810.
[http://dx.doi.org/10.1167/iovs.06-0216] [PMID: 16936091]
[20]
Bianchini, G.; De Angelis, C.; Licata, L.; Gianni, L. Treatment landscape of triple-negative breast cancer — expanded options, evolving needs. Nat. Rev. Clin. Oncol., 2022, 19(2), 91-113.
[http://dx.doi.org/10.1038/s41571-021-00565-2] [PMID: 34754128]
[21]
Schmid, P.; Rugo, H.S.; Adams, S.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Diéras, V.; Henschel, V.; Molinero, L.; Chui, S.Y.; Maiya, V.; Husain, A.; Winer, E.P.; Loi, S.; Emens, L.A. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol., 2020, 21(1), 44-59.
[http://dx.doi.org/10.1016/S1470-2045(19)30689-8] [PMID: 31786121]
[22]
Winer, E.P.; Lipatov, O.; Im, S.A.; Goncalves, A.; Muñoz-Couselo, E.; Lee, K.S.; Schmid, P.; Tamura, K.; Testa, L.; Witzel, I.; Ohtani, S.; Turner, N.; Zambelli, S.; Harbeck, N.; Andre, F.; Dent, R.; Zhou, X.; Karantza, V.; Mejia, J.; Cortes, J. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): A randomised, open-label, phase 3 trial. Lancet Oncol., 2021, 22(4), 499-511.
[http://dx.doi.org/10.1016/S1470-2045(20)30754-3] [PMID: 33676601]
[23]
Adams, S.; Schmid, P.; Rugo, H.S.; Winer, E.P.; Loirat, D.; Awada, A.; Cescon, D.W.; Iwata, H.; Campone, M.; Nanda, R.; Hui, R.; Curigliano, G.; Toppmeyer, D.; O’Shaughnessy, J.; Loi, S.; Paluch-Shimon, S.; Tan, A.R.; Card, D.; Zhao, J.; Karantza, V.; Cortés, J. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study. Ann. Oncol., 2019, 30(3), 397-404.
[http://dx.doi.org/10.1093/annonc/mdy517] [PMID: 30475950]
[24]
Jiang, T.; Wang, P.; Zhang, J.; Zhao, Y.; Zhou, J.; Fan, Y.; Shu, Y.; Liu, X.; Zhang, H.; He, J.; Gao, G.; Mu, X.; Bao, Z.; Xu, Y.; Guo, R.; Wang, H.; Deng, L.; Ma, N.; Zhang, Y.; Feng, H.; Yao, S.; Wu, J.; Chen, L.; Zhou, C.; Ren, S. Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: A multicenter phase-II trial. Signal Transduct. Target. Ther., 2021, 6(1), 355.
[http://dx.doi.org/10.1038/s41392-021-00751-9] [PMID: 34650034]
[25]
Yin, X.; Teng, X.; Ma, T.; Yang, T.; Zhang, J.; Huo, M.; Liu, W.; Yang, Y.; Yuan, B.; Yu, H.; Huang, W.; Wang, Y. RUNX2 recruits the NuRD(MTA1)/CRL4B complex to promote breast cancer progression and bone metastasis. Cell Death Differ., 2022, 29(11), 2203-2217.
[http://dx.doi.org/10.1038/s41418-022-01010-2] [PMID: 35534547]
[26]
Qian, X.L.; Xu, P.; Zhang, Y.Q.; Song, Y.M.; Li, Y.Q.; Li, W.D.; Jiang, C.Y.; Shen, B.B.; Zhang, X.M.; Zhang, L.N.; Fu, L.; Guo, X.J. Increased number of intratumoral IL-17+ cells, a harbinger of the adverse prognosis of triple-negative breast cancer. Breast Cancer Res. Treat., 2020, 180(2), 311-319.
[http://dx.doi.org/10.1007/s10549-020-05540-6] [PMID: 31993861]

Rights & Permissions Print Cite
Article Metrics
34
2
© 2024 Bentham Science Publishers | Privacy Policy